Year-to-Date Metrics and Trends for the Gene Therapy, Cell Therapy, Tissue Engineering,and Broader Regenerative Medicine Sector. ARM today released its most recent quarterly sector report, offering an in-depth look at the gene therapy, cell therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2019. By further curating information provided
Perianal fistulizing Crohn’s disease (PFCD) is associated with significant morbidity and might negatively impact the quality of life of CD patients. In the last two decades, the management of PFCD has evolved in terms of the multidisciplinary approach involving gastroenterologists and colorectal surgeons. However, the highest fistula healing rates, even combining surgical and anti-TNF agents,
Transporting irreplaceable products means having trust in the technology Cell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene
Novel automation technologies enable the decentralized manufacturing of highly standardized CAR-T cell products in academic GMP facilities experienced with the production of patient-individual cell therapies. Dr Janet Rossig discusses the benefits of academic cell manufacturing, namely supporting the informed dissemination of CAR-T cell therapy to patients who benefit from this modality. She argues that this
A phase I clinical trial is the first research monitored by the Food and Drug Administration that demonstrates the potential of regenerative therapy for hypoplastic left heart syndrome (HLHS) through collecting, processing and injecting an infant’s own stem cells directly into the heart at the time of surgery. A paper detailing the clinical trial was published in The
New research from the USC Viterbi School of Engineering could be key to our understanding of how the aging process works. The findings potentially pave the way for better cancer treatments and revolutionary new drugs that could vastly improve human health in the twilight years. The work, from Assistant Professor of Chemical Engineering and Materials
Researchers led by Pierre Vanderhaeghen and Jérôme Bonnefont (VIB-KU Leuven and ULB), in collaboration with Stein Aerts (VIB KU Leuven) and François Guillemot (Crick Institute), have unraveled a new mechanism controlling the switch between growth and differentiation of neural stem cells during brain development. They discovered a specific factor that makes stem cells ‘deaf’ to proliferative signals,
Researchers at King’s College London have used single cell RNA sequencing to identify a type of cell that may be able to regenerate liver tissue, treating liver failure without the need for transplants. In a paper published today in Nature Communications, the scientists have identified a new type of cell called a hepatobiliary hybrid progenitor (HHyP), that
Scientists have invented a synthetic protein designed to control the inner workings of cells. In a pair of papers, published yesterday (July 24) in Nature, the researchers demonstrate how the tool can be used to tweak gene expression, orchestrate protein binding events, and cue functional changes in the cell in response to environmental conditions. “Cells receive stimuli, then have
Cell therapies, in which cellular material is injected, grafted, or implanted into a patient to treat a range of illnesses and medical conditions, are a vital and integral component of medicine today — promising treatment of tissue degenerative diseases, cancer, and autoimmune disorders. However, significant challenges currently exist to prevent its widespread adoption, including problems
